Lam Nguyen-Ho, Nam Nguyen-Thanh, Vu Le-Thuong, Vinh Nguyen-Nhu, Tuyet-Lan Le-Thi
Department of Respiratory Functional Exploration, University Medical Center, Ho Chi Minh City, Vietnam.
University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam.
Asia Pac Allergy. 2021 Jan 26;11(1):e9. doi: 10.5415/apallergy.2021.11.e9. eCollection 2021 Jan.
Stepping down treatment for well-controlled mild asthma is challenging to clinicians. The step-down strategy using regularly-intermittent low-dose inhaled corticosteroid has been applied at the University Medical Center (UMC) of Ho Chi Minh City, called as "UMC" approach.
This study aimed to evaluate the efficiency of UMC step-down strategy in well- controlled mild asthma.
A real-world retrospective descriptive study was conducted at UMC from 2009 to 2018. All asthmatic patients (age ≥ 12) who received step-down therapy using this UMC approach were evaluated.
Among 2,072 asthma patients to be treated with UMC step-down strategy, only 112 subjects were eligible. The median age was 38.5 years and female was 62.5%. Most patients at their initial presentation were indicated step 4 treatment (87.5%). The controller medications before initiation of UMC treatment included fluticasone propionate 125 μg once-daily, salmeterol/fluticasone propionate 25/125 μg once-daily, and formoterol/budesonide 4.5/160 μg once-daily. After being treated with the UMC approach, the rates of well-controlled asthma ranged from 67.6% to 91.1%. During 1 year with UMC treatment, pulmonary function remained stable and only 7 subjects (6.3%) developed exacerbation.
The UMC step-down treatment for well-controlled mild asthma was relatively efficient in maintaining asthma control, stabilization of pulmonary function, and reducing risk of severe exacerbation.
对于病情得到良好控制的轻度哮喘患者,逐步减少治疗对临床医生来说具有挑战性。在胡志明市大学医学中心(UMC)应用了定期间歇性低剂量吸入糖皮质激素的逐步减量策略,即“UMC”方法。
本研究旨在评估UMC逐步减量策略在病情得到良好控制的轻度哮喘中的有效性。
于2009年至2018年在UMC进行了一项真实世界的回顾性描述性研究。对所有使用这种UMC方法接受逐步减量治疗的哮喘患者(年龄≥12岁)进行评估。
在2072例拟采用UMC逐步减量策略治疗的哮喘患者中,仅有112例符合条件。中位年龄为38.5岁,女性占62.5%。大多数患者在初次就诊时处于第4步治疗(87.5%)。开始UMC治疗前的控制药物包括每日一次的丙酸氟替卡松125μg、每日一次的沙美特罗/丙酸氟替卡松25/125μg以及每日一次的福莫特罗/布地奈德4.5/160μg。采用UMC方法治疗后,哮喘控制良好的比例在67.6%至91.1%之间。在接受UMC治疗的1年中,肺功能保持稳定,仅有7例患者(6.3%)病情加重。
对于病情得到良好控制的轻度哮喘,UMC逐步减量治疗在维持哮喘控制、稳定肺功能以及降低严重病情加重风险方面相对有效。